Aza-Phthalazine Compounds Modulating P38 Kinase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to treating pro-inflammatory cytokine-mediated diseases, such as those involving TNF-α, IL-1β, IL-6, and IL-8, are limited in effectively regulating cytokine production and alleviating inflammation, pain, and joint destruction in conditions like rheumatoid arthritis.
Innovation Solution
Development of a new class of compounds defined by Formula I, which modulate the p38 MAP kinase protein, allowing for the regulation of pro-inflammatory cytokine levels and the treatment of associated diseases through pharmaceutical compositions that inhibit p38 kinase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current approaches to treating pro-inflammatory cytokine-mediated diseases are used, then treatment options are limited, but the ability to effectively regulate cytokine production and alleviate inflammation is insufficient
Solution Approach 1:
The patent introduces a series of chemical compounds with varying molecular structures (Formula I with different R1, R2, R3, R5, A1, A2, A3, A4, L, and m parameters) that modulate p38 MAP kinase activity. By changing the chemical parameters of the compounds, the patent achieves different levels and types of cytokine production regulation, thereby improving treatment versatility while maintaining reliable cytokine regulation through the conserved p38 kinase inhibition mechanism.
2Reliability
If p38 kinase activity is inhibited to reduce cytokine production, then inflammatory diseases are treated, but the mechanism requires development of new compound classes
Solution Approach 1:
The patent segments the complex p38 kinase inhibition problem into manageable chemical building blocks. Formula I is divided into distinct substitutable components (R1, R2, R3, R5 groups and A1-A4 ring positions) that can be independently optimized. This segmentation allows systematic development of compound variants that achieve reliable therapeutic benefit while managing structural complexity through modular design.
Solution Approach 2:
The patent systematically varies chemical parameters (substituent types, ring positions, molecular weight, lipophilicity) within Formula I to optimize the balance between therapeutic efficacy and structural complexity. By changing these parameters, the patent generates a library of compounds with predictable activity profiles, making the complex inhibition mechanism controllable and developable.
Data Source
AI summary
The present invention comprises a new class of compounds useful for the prophylaxis and treatments of protein kinase mediated diseases, including inflammation and related conditions.